KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amgen (AMGN) Non Operating Income (2016 - 2025)

Amgen has reported Non Operating Income over the past 17 years, most recently at -$553.0 million for Q4 2025.

  • Quarterly results put Non Operating Income at -$553.0 million for Q4 2025, up 29.28% from a year ago — trailing twelve months through Dec 2025 was $2.7 billion (up 423.91% YoY), and the annual figure for FY2025 was $2.7 billion, up 423.91%.
  • Non Operating Income for Q4 2025 was -$553.0 million at Amgen, down from $2.1 billion in the prior quarter.
  • Over the last five years, Non Operating Income for AMGN hit a ceiling of $2.1 billion in Q3 2025 and a floor of -$782.0 million in Q4 2024.
  • Median Non Operating Income over the past 5 years was $12.0 million (2021), compared with a mean of $271.8 million.
  • Biggest five-year swings in Non Operating Income: plummeted 4176.92% in 2022 and later skyrocketed 745.96% in 2025.
  • Amgen's Non Operating Income stood at $162.0 million in 2021, then plummeted by 141.36% to -$67.0 million in 2022, then soared by 700.0% to $402.0 million in 2023, then tumbled by 294.53% to -$782.0 million in 2024, then grew by 29.28% to -$553.0 million in 2025.
  • The last three reported values for Non Operating Income were -$553.0 million (Q4 2025), $2.1 billion (Q3 2025), and -$394.0 million (Q2 2025) per Business Quant data.